BioWorld

Oct. 30, 2009

Another 'BiTE' as Micromet Inks Potential €320M Sanofi Alliance

With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound. (BioWorld Today) Read More

Transcept Plunges as FDA Cites Concerns About Insomnia Drug

Gene Fusions Are Not Random Events, but Aided by Hormones

Adjust-as-You-Go Trial Approach: Key to Pleasing FDA, Partners?

Aldagen Eyes Public Markets to Fund Two Phase III Efforts

Genta Crushed as Genasense Fails Another Phase III Study

Virdante Series A Brings in $47M to Boost New Antibody Program

Other News To Note

Clinic Roundup

Earnings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...